Produktbild
Andrew J. (Hrsg.) Krentz

Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease

A Focus on Early Phase Clinical Drug Development

Buch

This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders.Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies.  However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs.This book discusses the need fo… Mehr

CHF 211.00

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen

Produktdetails


Weitere Autoren: Weyer, Christian (Hrsg.) / Hompesch, Marcus (Hrsg.)
  • ISBN: 978-3-030-11747-4
  • EAN: 9783030117474
  • Produktnummer: 29541099
  • Verlag: Springer-Verlag GmbH
  • Sprache: Englisch
  • Erscheinungsjahr: 2019
  • Seitenangabe: 556 S.
  • Masse: H26.5 cm x B18.9 cm x D3.0 cm 1'470 g
  • Auflage: 2nd ed. 2019
  • Abbildungen: Book; 45 schwarz-weiße Abbildungen, Bibliographie
  • Gewicht: 1470

Über den Autor


Andrew J Krentz, Senior Research Fellow at ProSciento, is a clinical academic with more than three decades of experience in diabetes and cardiometabolic medicine. He is currently a visiting professor at the University of Reading, UK. Prior to this he was a senior physician and senior lecturer at University Hospital Southampton, UK. He has held research positions at the University of California San Diego and the New Mexico School of Medicine, USA. He is editor-in-chief of 'Cardiovascular Endocrinology & Metabolism' and has published more than 100 articles in peer-reviewed medical journals.Christian Weyer is a pharmaceutical executive with over 20 years of experience in the drug development focused on diabetes, obesity, and NAFLD/NASH.  As head of R&D at Amylin Pharmaceuticals and Intercept Pharmaceutics, he has contributed to the development, regulatory approval and/or life cycle management of several first-in-class medicines in the areas of type 1 and type 2 diabetes, lipodystrophy, and progressive non-viral liver diseases, as well as to the mid and late-stage development of novel drug candidates for obesity and NASH. Dr Weyer previously served as President and Chief Development Officer at ProSciento and as visiting fellow with the National Institutes of Health, NIDDK, and has authored over 100 peer-reviewed publications in the field of endocrinology and metabolism.  Marcus Hompesch, Chief Executive Officer and Chairman of the Board, ProSciento is a recognized expert in the field of metabolic diseases, a licensed physician and entrepreneur. His experience in designing, performing and publishing clinical studies in metabolic diseases has been gained through over 20 years of work as clinician and clinical researcher. To date Dr Hompesch has authored more than 90 publications, has been editor and author of a textbook on translational research methods and is editor-in-chief of the journal 'Endocrinology, Diabetes & Metabolism'. He established ProSciento, Inc., CA in 2003

4 weitere Werke von Andrew J. (Hrsg.) Krentz:


Bewertungen


0 von 0 Bewertungen

Geben Sie eine Bewertung ab!

Teilen Sie Ihre Erfahrungen mit dem Produkt mit anderen Kunden.